Article Text

Download PDFPDF

PR020/#632  Impact of the LACC trial on the oncologic outcomes of cervical cancer undergoing surgical treatment
  1. Gabriella Schivardi1,
  2. Luigi De Vitis1,
  3. Ludovica Nazzaro1,
  4. Michela Gaiano1,
  5. Maria Teresa Achilarre1,
  6. Alessia Aloisi1,
  7. Ilaria Betella1,
  8. Simone Bruni1,
  9. Annalisa Garbi1,
  10. Giovanni Aletti1,2,
  11. Vanna Zanagnolo1,
  12. Angelo Maggioni1,
  13. Nicoletta Colombo1,3 and
  14. Fancesco Multinu1
  1. 1IRCCS European Institute of Oncology, Gynaecological Surgery, Milan, Italy
  2. 2University of Milan, Oncology and Hemato-Oncology, Milan, Italy
  3. 3University of Milan-Bicocca and Gynecologic Oncology Program, European Institute of Oncology IRCCS, Department of Medicine and Surgery, Milan, Italy


Introduction The impact of the LACC trial’s results on oncologic outcome has not been assessed. This study aimed to compare 2-year recurrence-free survival before and after the LACC trial for cervical cancer patients undergoing surgical treatment.

Methods Cervical cancer patients who underwent radical hysterectomy and pelvic lymphadenectomy at the European Institute of Oncology, Milan from January 2010 to December 2021 were retrospectively identified. Following the LACC trial’s results, robotic-assisted surgery was limited to patients with no residual disease after conization. We performed univariate analysis to compare clinicopathological characteristics between the pre-LACC period (January 2010-March 2018) and post-LACC period (April 2018-December 2021). Survival analysis was performed using a log-rank test to compare 2-years recurrence-free survival during the pre- and post-LACC period.

Results Among 451 patients meeting inclusion criteria, 342 (75,8%) underwent surgery during the pre-LACC period and 109 (24,2%) during the post-LACC period. The rate of the robotic-assisted approach decreased from 60,8% to 23,8% from the pre- to the post-LACC period, while the open approach increased from 39,2% to 76,1% (p < 0.001). Recurrence was observed in 36 patients (8%) within the first 2 years following surgery. No recurrences were observed in patients treated with robotic-assisted surgery during the post-LACC period. No difference in 2-year recurrence-free survival was observed between the pre-and post-LACC period (p=0,45).

Conclusion/Implications The LACC trial led to a significant change in the surgical approach to cervical cancer. The decreased use of robotic surgery did not have an impact on the 2-year recurrence-free survival in our population.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.